MedTrace Logo

Medrol Dosepak for Outpatient Total Knee Arthroplasty

NCT05097976 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 420

Last updated 2026-04-14

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy of an oral methylprednisolone taper on acute postoperative pain, function, opioid consumption, nausea, and complications following outpatient total knee arthroplasty (TKA). We hypothesize that administration of an oral methylprednisolone taper starting on postoperative day 1 (POD 1) following TKA will be associated with improved pain and decreased opioid use, nausea, and complications at POD1-7, as compared to similar patients who receive placebo. Additionally, those taking methylprednisolone will report decreased pain and greater objective functional outcomes at 3 and 6 weeks postoperatively as compared to controls.

Conditions

  • Total Knee Arthroplasty

Interventions

DRUG

Methylprednisolone

21 x 4mg tablets beginning on POD 1

DRUG

Placebo

21 sugar tablets beginning on POD 1 with standard management

Sponsors & Collaborators

  • Rush University Medical Center

    lead OTHER

Principal Investigators

  • Craig Della Valle, MD · Rush University Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-03-01
Primary Completion
2026-05-30
Completion
2026-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05097976 on ClinicalTrials.gov